The latest price target for Pharming (NASDAQ:PHAR) was reported by HC Wainwright & Co. on March 21, 2025. The analyst firm set a price target for $37.00 expecting PHAR to rise to within 12 months (a possible 329.23% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Pharming (NASDAQ:PHAR) was provided by HC Wainwright & Co., and Pharming reiterated their buy rating.

There is no last upgrade for Pharming

There is no last downgrade for Pharming.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pharming, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pharming was filed on March 21, 2025 so you should expect the next rating to be made available sometime around March 21, 2026.

While ratings are subjective and will change, the latest Pharming (PHAR) rating was a reiterated with a price target of $37.00 to $37.00. The current price Pharming (PHAR) is trading at is $8.62, which is out of the analyst’s predicted range.